Home > Riviste > Minerva Pediatrica > Fascicoli precedenti > Articles online first > Minerva Pediatrica 2021 Jan 13

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Pediatrica 2021 Jan 13

DOI: 10.23736/S0026-4946.20.05881-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals

Magdalena PLUTA 1, 2 , Maria POKORSKA-ŚPIEWAK 1, 2, Małgorzata ANISZEWSKA 1, 2, Zbigniew LEWANDOWSKI 3, Barbara KOWALIK-MIKOŁAJEWSKA 1, 2, Magdalena MARCZYŃSKA 1, 2

1 Department of Children’s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland; 2 Hospital of Infectious Diseases, Warsaw, Poland; 3 Department of Epidemiology, Medical University of Warsaw, Warsaw, Poland


PDF


BACKGROUND: Therapy with pegylated interferon and ribavirin (PEG-IFN+RBV) for chronic hepatitis C (CHC) still remains the only option available for children in many Eurasian and European countries. Our aim was to evaluate the influence of host and viral factors on response to IFN-based therapy to optimize it for those in whom directly acting antivirals (DAA) are currently unavailable.
METHODS: Seventeen vertically infected, treatment naive children (10 male and 7 female) aged 5-16 years with CHC underwent a course of PEG-IFN+RBV. The end point was sustained virologic response (SVR). Host and virus factors were divided into pre- and ontreatment predictors of response to therapy.
RESULTS: Eleven patients obtained SVR (64%), 4 were nonresponders (23%), and 2 were relapsers (12%). Significant relationship was found between HCV RNA elimination and following variables: virus genotype and early virologic response (EVR) (p< .037, p< .029 respectively). Higher eradication rate was observed in patients infected with genotype 3 HCV (100% vs. 65% with genotype 1 or 4), and in those with undetectable HCV RNA by week 12 (88% vs. 66% with viremia). EVR was associated with SVR (83% vs. 0% in nonresponders; p< .004). C allele of IL28B rs12979860 was a predictor of EVR (p < .043). The SVR rates among CC, CT, and TT carriers were as follows: 75%, 67%, and 33%.
CONCLUSIONS: Detection of favourable HCV and IL28B genotype prior to commencement of PEG-IFN+RBV, and continuing it in patients with EVR is of major importance for those in whom DAA are still unavailable.


KEY WORDS: HCV in children; DAA; Pegylated interferon; SVR; Interleukin 28B

inizio pagina